I have consistently talked up PRO 140 for monotherapy. I have consistently said the drug works well and its tests should continue to show that. I have consistently said CYDY has some really big financing hurdles, which is pretty obvious and that it would be best to buy after the last big capital raise has occurred (or maybe participate in it). I have consistently said Ibalizumab is a superior drug to PRO 140 in MDER patients and the facts bear that out. I am just reporting it as I see it and I know that sometimes makes the bulls hear feel a bit bad but I am not a basher. And, you would have done well to buy Theratechnologies and not buy CYDY over the last year, so I should get a little credit for being right, don't you think. I am happy to debate and learn about these two drugs, so feel free to make your points as well. Should I question your bullishness as being somehow biased as you are questioning my concerns about CYDY? I don't - I just share info that I think would be worthwhile and any fair reading of my posts would indicate they have been very useful. You are free to ignore them but I prefer if you raise good counterpoints so I can learn - that is the purpose of these boards. I have consistently said that if CYDY can navigate the financial challenges it faces and get PRO 140 approved for monotherapy, it has a lot of upside. If it can, I hope to be along for the ride as it should be a very big ride higher. But anyone can see that the company is on the ropes financially at the moment. I expect it will survive but worry current shareholders could pay a big price in the process. So buying later rather than sooner seems sensible to me.
News 
Market Data 
Discover 
AI
